Ben Collman
About Ben Collman
Ben Collman serves as the Executive Director of Drug Product at BridgeBio, bringing over 22 years of experience in drug substance and drug product development across various pharmaceutical companies.
Current Role at BridgeBio
Ben Collman serves as the Executive Director of Drug Product at BridgeBio, a position he has held since 2023. In this role, he is responsible for overseeing drug product manufacturing development, ensuring that processes are executed efficiently at both pilot and commercial scales. His expertise in pharmaceutical processes contributes to the advancement of drug development initiatives within the organization.
Previous Experience in Pharmaceutical Companies
Ben Collman has over 22 years of experience in drug substance and drug product development across various pharmaceutical companies. He has held significant roles at notable organizations, including Pfizer Pharmaceuticals, where he worked as a Scientist for ten years, and AbbVie, where he served as Senior Scientist II. His tenure at Ardelyx, Inc. as a Senior Scientist from 2016 to 2019 further solidified his expertise in the field.
Education and Academic Background
Ben Collman studied at Hope College from 1996 to 1998 for two years before continuing his education at Eastern Michigan University. His academic background has provided a foundation for his extensive career in pharmaceutical development, equipping him with the knowledge necessary to excel in various scientific roles.
Expertise in Pharmaceutical Processes
Ben Collman possesses a broad range of expertise in pharmaceutical processes. He is skilled in hot melt extrusion, wet granulation, and roller compaction. His experience includes characterization of active pharmaceutical ingredients (API), in-vitro modeling, and stable polymorph screening. He has also been involved in NDA filing and has experience with bilayer tablets and amorphous solid dispersion.
Specialized Skills in Drug Development
Collman specializes in the management and execution of drug product manufacturing development. He is proficient in drafting, reviewing, and executing development and clinical batch records. His skills extend to cocrystal screening, hydrate screening, and R&D solid form nomination, as well as expertise in drug product and drug substance intellectual property and tech transfer.